Himly Martin, Jahn-Schmid Beatrice, Dedic Azra, Kelemen Peter, Wopfner Nicole, Altmann Friedrich, van Ree Ronald, Briza Peter, Richter Klaus, Ebner Christof, Ferreira Fátima
Institute of Genetics and General Biology, University of Salzburg, A-5020 Salzburg, Austria.
FASEB J. 2003 Jan;17(1):106-8. doi: 10.1096/fj.02-0472fje. Epub 2002 Nov 15.
In late summer, pollen grains originating from Compositae weeds (e.g., mugwort, ragweed) are a major source of allergens worldwide. Here, we report the isolation of a cDNA clone coding for Art v 1, the major allergen of mugwort pollen. Sequence analysis showed that Art v 1 is a secreted allergen with an N-terminal cysteine-rich domain homologous to plant defensins and a C-terminal proline-rich region containing several (Ser/Ala)(Pro)2-4 repeats. Structural analysis showed that some of the proline residues in the C-terminal domain of Art v 1 are posttranslationally modified by hydroxylation and O-glycosylation. The O-glycans are composed of 3 galactoses and 9-16 arabinoses linked to a hydroxyproline and represent a new type of plant O-glycan. A 3-D structural model of Art v 1 was generated showing a characteristic "head and tail" structure. Evaluation of the antibody binding properties of natural and recombinant Art v 1 produced in Escherichia coli revealed the involvement of the defensin fold and posttranslational modifications in the formation of epitopes recognized by IgE antibodies from allergic patients. However, posttranslational modifications did not influence T-cell recognition. Thus, recombinant nonglycosylated Art v 1 is a good starting template for engineering hypoallergenic vaccines for weed-pollen therapy.
夏末,源自菊科杂草(如艾蒿、豚草)的花粉粒是全球主要的过敏原来源。在此,我们报告了编码艾蒿花粉主要过敏原Art v 1的cDNA克隆的分离。序列分析表明,Art v 1是一种分泌型过敏原,其N端富含半胱氨酸结构域与植物防御素同源,C端富含脯氨酸区域包含几个(Ser/Ala)(Pro)2 - 4重复序列。结构分析表明,Art v 1 C端结构域中的一些脯氨酸残基在翻译后被羟基化和O - 糖基化修饰。O - 聚糖由3个半乳糖和9 - 16个阿拉伯糖连接到一个羟脯氨酸组成,代表一种新型的植物O - 聚糖。生成了Art v 1的三维结构模型,显示出特征性的“头和尾”结构。对天然和在大肠杆菌中产生的重组Art v 1的抗体结合特性评估表明,防御素折叠和翻译后修饰参与了过敏性患者IgE抗体识别的表位形成。然而,翻译后修饰不影响T细胞识别。因此,重组非糖基化Art v 1是用于杂草花粉治疗的低变应原性疫苗工程的良好起始模板。